UNSPSC 51111810: Testolactone

This classification denotes a steroidal aromatase inhibitor with the molecular formula C19H24O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6J9BLA949Q, chemically known as d-homo-17a-oxaandrosta-1,4-diene-3,17-dione but generally known as testolactone, which bears US NIH Compound Identifier 5407. European Medicines Agency schedules Testolactone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10936MIG. The term TESTOLACTONE is an International Non-Proprietary Name.

UNSPSC 51111810 Testolactone is a Commodity code for pharmaceutical products, specifically an anabolic steroid used in cancer treatment. State and local government entities purchasing under this code acquire generic pharmaceuticals and over-the-counter products through cooperative purchasing agreements that consolidate demand across multiple jurisdictions and facility types, including state agencies, local government offices, schools, and healthcare systems. Recent solicitation activity shows that procurement is structured around multi-source pharmaceutical contracts with detailed product specification requirements, including National Drug Codes (NDCs), packaging configurations, and manufacturing locations. Vendors must maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), establish relationships with authorized wholesalers, and offer flexible pricing models such as flat price, net price formats, or WAC-minus structures. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a dominant issuing body in this category, consolidating purchasing across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions.

MMCAP's current RFP for generic multi-source pharmaceuticals and OTC products, issued January 20, 2026 with a March 26, 2026 response deadline, exemplifies current market activity. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded agreements effective July 1, 2026. Evaluation prioritizes price competitiveness at 75 percent of scoring, with secondary weight given to fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must carry comprehensive insurance including $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability. The contract term is two years for new vendors with optional extensions, while incumbent responders' amendments extend through June 30, 2028. No specific set-aside designations are identified in the available solicitation materials.